Locations:
October 8, 2021/Cancer

Stereotactic Radiosurgery for Brain Metastases (Podcast)

Why it remains the mainstay for newly diagnosed metastases and tumors

Cleveland Clinic Cancer Advances · Stereotactic Radiosurgery in the Treatment Landscape for Brain Metastases

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Brain metastases are about 10 times more common than primary brain tumors in adults, so it is really important that medical oncologists and primary care doctors are tuned into the possibility of their patients with cancer developing brain metastases,” says neurosurgeon Gene Barnett, MD, MBA, Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “The treatment options are better if we get to these metastases when they are smaller and/or asymptomatic.”

One treatment option is stereotactic radiosurgery, a minimally invasive intervention that uses targeted radiation beams to treat brain tumors and other abnormalities. In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Barnett discusses the evolution of traditional surgical approaches for treating patients with brain metastases and the ability of stereotactic radiosurgery to deliver superior outcomes. He provides insight on the following:

  • Presenting symptoms of brain metastases
  • The range of treatment options, from surgical interventions to medication and radiation therapies
  • A step-by-step look at the stereotactic radiosurgery procedure
  • The emergence and promising results of neoadjuvant stereotactic surgery
  • The importance of combining systemic therapies with radiosurgery for tumor control

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt.

Excerpt from the podcast

Podcast host Dale Shepard, MD, PhD: What does [stereotactic radiosurgery] look like from a patient perspective, in terms of what their experience is as they undergo the treatment and how well they’re likely to do? When I see patients in clinic and I tell them they have a lung met or a liver met, they’re not nearly as frightened as when I tell them they have a brain met. So how do we reassure patients?

Advertisement

Dr. Barnett: Well, I think that’s totally understandable because people understand the brain is who we are and allows us to do what we want to do. Many people know, or know of, people who have had brain tumors and have not done well. I think the point of reassurance is that we can actually do a really good job of controlling brain metastases these days with radiosurgery, to the extent that most people who have brain metastases don’t die from them — rather, they die of their systemic disease and their brain disease is under control. For the vast majority of brain metastases, the control rate is upwards of 90% to 95%. And with the staged technique, the control is typically durable. So, I think that giving patients the facts should be consoling. You don’t want to sugarcoat things, but the facts are that the outcome is actually probably a lot better than what they were thinking.

Advertisement

Related Articles

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Lung cancer illustration
September 29, 2026/Cancer/Radiation Oncology

Single-Fraction SBRT Shows Comparable Outcomes to Three-Fraction Approach in Early-Stage Lung Cancer

Large Cleveland Clinic analysis may help resolve a longstanding question over optimal fractionation

Ad